<DOC>
	<DOC>NCT00633893</DOC>
	<brief_summary>The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)</brief_summary>
	<brief_title>Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>Men and women â‰¥ 18 years of age; Clinical diagnosis of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE); Anticoagulant treatment completed No recurrence of Venous Thromboembolism (VTE) Subjects with indications for longterm treatment with a vitamin K antagonist Active bleeding or high risk for serious bleeding Short life expectancy Uncontrolled high blood pressure Impaired kidney or liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>